Buy Or Sell Opportunity • Aug 11
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 7.9% to €1.97. The fair value is estimated to be €2.47, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.3% over the last 3 years. Earnings per share has grown by 76%. Reported Earnings • Aug 09
Second quarter 2026 earnings released: EPS: JP¥0.75 (vs JP¥0.38 loss in 2Q 2025) Second quarter 2026 results: EPS: JP¥0.75 (up from JP¥0.38 loss in 2Q 2025). Revenue: JP¥13.3b (up 5.5% from 2Q 2025). Net income: JP¥105.0m (up JP¥157.0m from 2Q 2025). Profit margin: 0.8% (up from net loss in 2Q 2025). The move to profitability was driven by higher revenue. Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. Annuncio • Aug 04
Blue Industries Inc. acquired GeneQuest Inc. from Euglena Co., Ltd. (TSE:2931). Blue Industries Inc. acquired GeneQuest Inc. from Euglena Co., Ltd. (TSE:2931) on August 1, 2026. Following the transaction, GeneQuest Inc. operates as a wholly owned subsidiary of Blue Industries Inc.
Post-acquisition, Osamu Iwata will continue to serve as Representative Director of GeneQuest Inc. Kyoichi Toda was appointed as a Director, Ryusuke Kuji as an Outside Director, and Kanako Sugishita as an Auditor. Shuji Tanahashi resigned from his position as Auditor. Additionally, GeneQuest Inc. is scheduled to relocate its headquarters to Chuo-ku, Tokyo.
Blue Industries Inc. completed the acquisition of GeneQuest Inc. from Euglena Co., Ltd. (TSE:2931) on August 1, 2026. Buy Or Sell Opportunity • Jun 15
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 13% to €1.80. The fair value is estimated to be €2.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.1% over the last 3 years. Earnings per share has grown by 66%. Annuncio • Jun 01
Euglena Co., Ltd. to Report Q2, 2026 Results on Aug 07, 2026 Euglena Co., Ltd. announced that they will report Q2, 2026 results on Aug 07, 2026 Reported Earnings • May 20
First quarter 2026 earnings released: JP¥0.23 loss per share (vs JP¥3.72 loss in 1Q 2025) First quarter 2026 results: JP¥0.23 loss per share (improved from JP¥3.72 loss in 1Q 2025). Revenue: JP¥13.2b (up 11% from 1Q 2025). Net loss: JP¥32.0m (loss narrowed 94% from 1Q 2025). Revenue is forecast to grow 2.3% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings. Annuncio • Feb 16
Euglena Co., Ltd., Annual General Meeting, Mar 24, 2026 Euglena Co., Ltd., Annual General Meeting, Mar 24, 2026. Annuncio • Dec 03
Euglena Co., Ltd. to Report Fiscal Year 2025 Results on Feb 13, 2026 Euglena Co., Ltd. announced that they will report fiscal year 2025 results on Feb 13, 2026 Annuncio • Sep 03
Euglena Co., Ltd. to Report Q3, 2025 Results on Nov 13, 2025 Euglena Co., Ltd. announced that they will report Q3, 2025 results on Nov 13, 2025 Annuncio • Aug 19
Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2025 Euglena Co., Ltd. provided consolidated earnings guidance for the year ending December 31, 2025. For the year, the company expects net sales of JPY 50,000 million and operating profit of JPY 2,400 million. Annuncio • Jun 03
Euglena Co., Ltd. to Report Q2, 2025 Results on Aug 08, 2025 Euglena Co., Ltd. announced that they will report Q2, 2025 results on Aug 08, 2025 Annuncio • Mar 01
Euglena Co., Ltd. to Report Q1, 2025 Results on May 12, 2025 Euglena Co., Ltd. announced that they will report Q1, 2025 results on May 12, 2025 Annuncio • Feb 14
Euglena Co., Ltd., Annual General Meeting, Mar 28, 2025 Euglena Co., Ltd., Annual General Meeting, Mar 28, 2025. Annuncio • Dec 03
Euglena Co., Ltd. to Report Fiscal Year 2024 Results on Feb 14, 2025 Euglena Co., Ltd. announced that they will report fiscal year 2024 results on Feb 14, 2025 Reported Earnings • Nov 13
Third quarter 2024 earnings released: JP¥5.73 loss per share (vs JP¥2.98 loss in 3Q 2023) Third quarter 2024 results: JP¥5.73 loss per share (further deteriorated from JP¥2.98 loss in 3Q 2023). Revenue: JP¥11.6b (up 3.1% from 3Q 2023). Net loss: JP¥781.0m (loss widened 124% from 3Q 2023). Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. Annuncio • Aug 27
Euglena Co., Ltd. to Report Q3, 2024 Results on Nov 11, 2024 Euglena Co., Ltd. announced that they will report Q3, 2024 results on Nov 11, 2024 Annuncio • Aug 14
Euglena Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended December 31, 2024 Euglena Co., Ltd. revised consolidated earnings guidance for the year ended December 31, 2024. for the year, the company expects Net sales of JPY 48,000 million. New Risk • Aug 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Annuncio • Jun 02
Euglena Co., Ltd. to Report Q2, 2024 Results on Aug 08, 2024 Euglena Co., Ltd. announced that they will report Q2, 2024 results on Aug 08, 2024 Annuncio • May 17
Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2024 Euglena Co., Ltd. provided consolidated earnings guidance for the year ended December 31, 2024. for the year, the company expects Net sales of JPY 52,500 million. Reported Earnings • May 16
First quarter 2024 earnings released: EPS: JP¥1.48 (vs JP¥1.45 loss in 1Q 2023) First quarter 2024 results: EPS: JP¥1.48 (up from JP¥1.45 loss in 1Q 2023). Revenue: JP¥11.2b (up 2.9% from 1Q 2023). Net income: JP¥191.0m (up JP¥358.0m from 1Q 2023). Profit margin: 1.7% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings. Annuncio • Mar 29
Euglena Co., Ltd. to Report Q1, 2024 Results on May 13, 2024 Euglena Co., Ltd. announced that they will report Q1, 2024 results on May 13, 2024 Reported Earnings • Mar 26
Full year 2023 earnings released: JP¥22.75 loss per share (vs JP¥23.83 loss in FY 2022) Full year 2023 results: JP¥22.75 loss per share (improved from JP¥23.83 loss in FY 2022). Revenue: JP¥46.5b (up 4.7% from FY 2022). Net loss: JP¥2.65b (flat on FY 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings. Annuncio • Feb 16
Euglena Co., Ltd., Annual General Meeting, Mar 19, 2024 Euglena Co., Ltd., Annual General Meeting, Mar 19, 2024. Reported Earnings • Feb 16
Full year 2023 earnings released: JP¥22.75 loss per share (vs JP¥23.83 loss in FY 2022) Full year 2023 results: JP¥22.75 loss per share (improved from JP¥23.83 loss in FY 2022). Revenue: JP¥46.5b (up 4.7% from FY 2022). Net loss: JP¥2.65b (flat on FY 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings. Annuncio • Jan 25
Zenhoren Co.,Ltd. (TSE:5845) agreed to acquire 18.93% stake in Okinawa Basketball Co., Ltd from Euglena Co., Ltd. (TSE:2931) for ¥360 million. Zenhoren Co.,Ltd. (TSE:5845) agreed to acquire 18.93% stake in Okinawa Basketball Co., Ltd from Euglena Co., Ltd. (TSE:2931) for ¥360 million on January 24, 2024. As part of acquisition, 480 shares will be acquired for ¥0.75 million. The transaction is expected to complete on January 31, 2024. Annuncio • Jan 12
Euglena Co., Ltd. (TSE:2931) agreed to acquire Saticine Medical Co., Ltd. Euglena Co., Ltd. (TSE:2931) agreed to acquire Saticine Medical Co., Ltd. on January 10, 2024. Board Change • Jan 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 3 highly experienced directors. Independent Outside Director Aiko Mochizuki was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annuncio • Dec 05
Euglena Co., Ltd. to Report Fiscal Year 2023 Results on Feb 14, 2024 Euglena Co., Ltd. announced that they will report fiscal year 2023 results on Feb 14, 2024 Reported Earnings • Nov 15
Third quarter 2023 earnings released: JP¥2.98 loss per share (vs JP¥15.91 loss in 3Q 2022) Third quarter 2023 results: JP¥2.98 loss per share (improved from JP¥15.91 loss in 3Q 2022). Revenue: JP¥11.3b (down 6.5% from 3Q 2022). Net loss: JP¥349.0m (loss narrowed 81% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Annuncio • Sep 02
Euglena Co., Ltd. to Report Q3, 2023 Results on Nov 13, 2023 Euglena Co., Ltd. announced that they will report Q3, 2023 results on Nov 13, 2023 Reported Earnings • Aug 16
Second quarter 2023 earnings released Second quarter 2023 results: JP¥6.38 loss per share. Net loss: JP¥747.0m (flat on 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 5.1% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 6% per year. Annuncio • Jun 28
Euglena Co., Ltd. to Report Q2, 2023 Results on Aug 14, 2023 Euglena Co., Ltd. announced that they will report Q2, 2023 results on Aug 14, 2023 Reported Earnings • May 17
First quarter 2023 earnings released First quarter 2023 results: JP¥1.45 loss per share. Net loss: JP¥167.0m (flat on 1Q 2022). Revenue is forecast to grow 1.0% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 1% per year. Reported Earnings • Mar 31
Full year 2022 earnings released: JP¥23.83 loss per share (vs JP¥44.51 loss in FY 2021) Full year 2022 results: JP¥23.83 loss per share (improved from JP¥44.51 loss in FY 2021). Revenue: JP¥44.4b (up 46% from FY 2021). Net loss: JP¥2.67b (loss narrowed 43% from FY 2021). Revenue is forecast to stay flat during the next 3 years compared to a 4.8% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Annuncio • Feb 16
Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending Dec. 31, 2023 Euglena Co., Ltd. provided consolidated earnings guidance for the fiscal year ending Dec. 31, 2023. The company expects net sales to be JPY 45,000 million. Annuncio • Feb 15
Euglena Co., Ltd., Annual General Meeting, Mar 24, 2023 Euglena Co., Ltd., Annual General Meeting, Mar 24, 2023. Reported Earnings • Feb 14
Full year 2022 earnings released: JP¥23.83 loss per share (vs JP¥44.51 loss in FY 2021) Full year 2022 results: JP¥23.83 loss per share (improved from JP¥44.51 loss in FY 2021). Revenue: JP¥44.4b (up 46% from FY 2021). Net loss: JP¥2.67b (loss narrowed 43% from FY 2021). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Annuncio • Feb 08
Euglena Co., Ltd. announced that it has received ¥7.7999475 billion in funding from Marui Group Co., Ltd., Rohto Pharmaceutical Co.,Ltd., Mazda Motor Corporation, Dai-ichi Life Holdings, Inc. On February 6, 2023, Euglena Co., Ltd. closed the transaction. Annuncio • Jan 20
Euglena Co., Ltd. announced that it expects to receive ¥7.7999475 billion in funding from Marui Group Co., Ltd., Rohto Pharmaceutical Co.,Ltd. Euglena Co., Ltd. announced that it will issue 3,208,500 common shares at a price of ¥935 for gross proceeds of ¥2,999,947,500 and 48 convertible bond-type bonds with stock acquisition rights at a price of ¥100,000,000 for gross proceeds of ¥4,800,000,000 for aggregate gross proceeds of ¥4,785,000,000 on January 19, 2023. The transaction will include participation from Marui Group Co., Ltd. of 2,139,000 shares and Rohto Pharmaceutical Co.,Ltd. of 1,069,500 shares post completion of the transaction. The company is issuing securities through third party allotment. The 10th stock acquisition rights are convertible into 5,133,689 shares. The transaction is expected to close on February 6, 2023. The transaction has been approved by the board of directors of the company. Annuncio • Dec 28
Euglena Co., Ltd. to Report Fiscal Year 2022 Results on Feb 13, 2023 Euglena Co., Ltd. announced that they will report fiscal year 2022 results on Feb 13, 2023 Annuncio • Nov 17
Euglena Co., Ltd. Provides Consolidated Financial Guidance for the Year Ending December 31, 2022 Euglena Co., Ltd. provided consolidated financial guidance for the year ending December 31, 2022. For the year, the company expects net sales of JPY 44,000 million. Annuncio • Aug 16
Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022 Euglena Co., Ltd. provided consolidated earnings guidance for the year ending December 31, 2022. For the year, the company expects net sales of JPY 44,000 million. Annuncio • Jun 10
Euglena Co., Ltd. to Report Q2, 2022 Results on Aug 10, 2022 Euglena Co., Ltd. announced that they will report Q2, 2022 results on Aug 10, 2022 Annuncio • May 18
Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022 Euglena Co., Ltd. provided consolidated earnings guidance for the year ending December 31, 2022. For the year, the company expects net sales of JPY 48,000 million. Annuncio • Apr 07
Euglena Co., Ltd. to Report Q1, 2022 Results on May 13, 2022 Euglena Co., Ltd. announced that they will report Q1, 2022 results on May 13, 2022 Reported Earnings • Apr 02
Full year 2021 earnings released: JP¥44.51 loss per share (vs JP¥17.15 loss in FY 2020) Full year 2021 results: JP¥44.51 loss per share (down from JP¥17.15 loss in FY 2020). Revenue: JP¥30.5b (up 118% from FY 2020). Net loss: JP¥4.68b (loss widened 194% from FY 2020). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Annuncio • Feb 22
Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022 Euglena Co., Ltd. provided consolidated earnings guidance for the year ending December 31, 2022. For the year, the company expects net sales of JPY 48,000 million. Annuncio • Feb 12
Euglena Co., Ltd., Annual General Meeting, Mar 26, 2022 Euglena Co., Ltd., Annual General Meeting, Mar 26, 2022. Reported Earnings • Feb 11
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: JP¥44.51 loss per share (down from JP¥17.15 loss in FY 2020). Revenue: JP¥30.5b (up 118% from FY 2020). Net loss: JP¥4.68b (loss widened 194% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Annuncio • Nov 27
Euglena Co., Ltd. Provides Earnings Guidance for the Period from October 1, 2020 to December 31, 2021 Euglena Co., Ltd. provided earnings guidance for the period from October 1, 2020 to December 31, 2021. For the period, the company expects net sales of ¥33,000 million. Annuncio • May 25
Euglena Co., Ltd. Provides Consolidated Sales Guidance for the Full Year Ending September 30, 2021 Euglena Co., Ltd. provided consolidated sales guidance for the full year ending September 30, 2021. For the year, the company expects net sales of JPY 22,000 million. Breakeven Date Change • May 17
Forecast to breakeven in 2022 The analyst covering Euglena expects the company to break even for the first time. New forecast suggests the company will make a profit of JP¥700.0m in 2022. Average annual earnings growth of 53% is required to achieve expected profit on schedule. Reported Earnings • May 17
Second quarter 2021 earnings released: EPS JP¥1.75 (vs JP¥1.17 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥3.83b (up 34% from 2Q 2020). Net income: JP¥164.0m (up 51% from 2Q 2020). Profit margin: 4.3% (up from 3.8% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Annuncio • Mar 16
Euglena Co., Ltd., Chevron Lummus Global and Applied Research Associates, Inc. Announce Successful Production of Renewable Jet Fuel Euglena Co., Ltd. (Euglena), Chevron Lummus Global (CLG) and Applied Research Associates, Inc. (ARA) are pleased to announce the successful production of renewable jet fuel from a blendstock of microalgae "euglena"-derived lipids, the first in the world to meet ASTM International D7566 Annex 6 standards. The recently produced renewable jet fuel was examined and certified to meet ASTM D7566 Annex 6 standards by a third-party analysis organization. ASTM standards are the most authoritative international fuel standards for aviation turbines produced from bio-based feedstocks. ASTM, the American Society for Testing and Materials, specify the means and testing methods for a wide variety of industrial materials. Annuncio • Mar 03
Euglena Co., Ltd. to Report Q2, 2021 Results on May 14, 2021 Euglena Co., Ltd. announced that they will report Q2, 2021 results on May 14, 2021 Reported Earnings • Feb 18
First quarter 2021 earnings released: JP¥3.87 loss per share (vs JP¥2.71 loss in 1Q 2020) The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: JP¥3.91b (up 22% from 1Q 2020). Net loss: JP¥360.0m (loss widened 43% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Is New 90 Day High Low • Feb 08
New 90-day high: €7.55 The company is up 9.0% from its price of €6.95 on 10 November 2020. The German market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is down 7.0% over the same period. Annuncio • Jan 22
Euglena Co., Ltd. (TSE:2931) entered into an agreement to acquire Liguna, K.K. from Noriko Minamizawa and Takeshi Matsumoto. Euglena Co., Ltd. (TSE:2931) entered into an agreement to acquire Liguna, K.K. from Noriko Minamizawa and Takeshi Matsumoto on January 21, 2021. Noriko Minamizawa will sell off 51.67% stake and Takeshi Matsumoto will sell 48.33% stake. Euglena Co., Ltd. will acquire 6000 shares of Liguna and the consideration will be paid in stock. Liguna, K.K. will operate as the wholly owned subsidiary of Euglena Co., Ltd. post completion of the transaction. For the year ending May 2020, Liguna reported net worth of ¥676 million, total assets of ¥1.51 billion, sales of ¥1.83 billion and operating income of ¥109 million. The transaction is subject to approval from shareholders of Liguna and is expected to complete on March 1, 2021. Annuncio • Jan 07
Euglena Co., Ltd. to Report Q1, 2021 Results on Feb 15, 2021 Euglena Co., Ltd. announced that they will report Q1, 2021 results on Feb 15, 2021 Reported Earnings • Dec 26
Full year 2020 earnings released: JP¥16.00 loss per share The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: JP¥13.3b (down 4.7% from FY 2019). Net loss: JP¥1.49b (loss narrowed 85% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Dec 24
New 90-day low: €6.05 The company is down 20% from its price of €7.55 on 25 September 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 2.0% over the same period. Is New 90 Day High Low • Dec 02
New 90-day low: €6.30 The company is down 3.0% from its price of €6.50 on 03 September 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 6.0% over the same period. Reported Earnings • Nov 19
Full year 2020 earnings released: JP¥16.00 loss per share The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: JP¥13.3b (down 4.7% from FY 2019). Net loss: JP¥1.49b (loss narrowed 85% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Annuncio • Nov 15
Euglena Co., Ltd., Annual General Meeting, Dec 18, 2020 Euglena Co., Ltd., Annual General Meeting, Dec 18, 2020. Annuncio • Oct 08
Euglena Co., Ltd. to Report Fiscal Year 2020 Results on Nov 13, 2020 Euglena Co., Ltd. announced that they will report fiscal year 2020 results on Nov 13, 2020 Annuncio • Jul 30
Euglena Co., Ltd. (TSE:2931) cancelled the acquisition of MEJ Inc. from Toru Koga and others. Euglena Co., Ltd. (TSE:2931) signed a share exchange contract to acquire MEJ Inc. from Toru Koga and others for approximately ¥670 million on May 8, 2019. Pursuant to the terms of the transaction Euglena Co., Ltd will issue 17 shares against one share of MEJ Inc. Euglena Co., Ltd will issue 0.9 million shares as consideration upon the delivery of MEJ Inc shares. Euglena Co., Ltd will acquire 51,850 outstanding shares of MEJ by share exchange, and make MEJ into a wholly owned subsidiary. MEJ Ltd reported total assets of ¥1.2 billion and net assets of ¥233 million as of September 30, 2018 and revenues of ¥721 million and operating profit of ¥57 million for the year ended September 30, 2018. The transaction is subject to approval by shareholders of MEJ in a meeting to be held on May 23, 2019. The transaction is resolved by the Board of Euglena Co., Ltd. The transaction is expected to complete on June 1, 2019. Plutus Consulting acted as third party appraiser and Miyake Imai Ikeda acted as legal advisor for Euglena Co., Ltd.
Euglena Co., Ltd. (TSE:2931) cancelled the acquisition of MEJ Inc. from Toru Koga and others on May 8, 2020.